ATE540952T1 - Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese - Google Patents

Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese

Info

Publication number: ATE540952T1
Authority: AT; Austria
Prior art keywords: pyrroloä2; düpyrimidine; synthesis; derivatives; intermediate products
Prior art date: 2005-07-29

Application number

AT06779900T

Other languages

English (en)

Inventor

Sally Gut Ruggeri

Joel Michael Hawkins

Teresa Margaret Makowski

Jennifer Lea Rutherford

Frank John Urban

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-29

Filing date

2006-07-17

Publication date

2012-01-15

2006-07-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE540952T1 publication Critical patent/ATE540952T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT06779900T 2005-07-29 2006-07-17 Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese ATE540952T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US70401105P	2005-07-29	2005-07-29
PCT/IB2006/002048 WO2007012953A2 (en)	2005-07-29	2006-07-17	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis

Publications (1)

Publication Number	Publication Date
ATE540952T1 true ATE540952T1 (de)	2012-01-15

Family

ID=36950230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06779900T ATE540952T1 (de)	2005-07-29	2006-07-17	Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese

Country Status (24)

Country	Link
US (2)	US8232394B2 (de)
EP (1)	EP1913000B1 (de)
JP (1)	JP4052523B2 (de)
KR (1)	KR100987870B1 (de)
CN (1)	CN101233138A (de)
AR (1)	AR056004A1 (de)
AT (1)	ATE540952T1 (de)
AU (1)	AU2006273762A1 (de)
BR (1)	BRPI0613876A2 (de)
CA (1)	CA2614907C (de)
CY (1)	CY1112319T1 (de)
DK (1)	DK1913000T3 (de)
ES (1)	ES2377771T3 (de)
IL (1)	IL188372A0 (de)
MX (1)	MX2008001334A (de)
NZ (1)	NZ565363A (de)
PL (1)	PL1913000T3 (de)
PT (1)	PT1913000E (de)
RU (1)	RU2384583C2 (de)
SG (1)	SG170783A1 (de)
SI (1)	SI1913000T1 (de)
TW (1)	TWI319402B (de)
WO (1)	WO2007012953A2 (de)
ZA (1)	ZA200800284B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101258316B1 (ko)	2007-07-11	2013-04-30	화이자 인코포레이티드	안구 건조증 치료용 약학 조성물 및 방법
EP3026052A1 (de)	2009-04-20	2016-06-01	Auspex Pharmaceuticals, Inc.	Vobereitung von deuterierte piperidinhemmer der janus-kinase 3
TW201120041A (en) *	2009-09-10	2011-06-16	Hoffmann La Roche	Inhibitors of JAK
CN102574860A (zh)	2009-10-15	2012-07-11	辉瑞大药厂	吡咯并[2,3-d]嘧啶化合物
EP2513114B1 (de)	2009-12-18	2014-04-02	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine
WO2011086053A1 (en)	2010-01-12	2011-07-21	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof
CA2788071A1 (en)	2010-02-05	2011-08-11	Pfizer Inc.	Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
CN103459394B (zh)	2011-04-08	2016-04-27	辉瑞大药厂	结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
US8993756B2 (en)	2011-12-06	2015-03-31	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
EP3170826A1 (de) *	2011-12-15	2017-05-24	ratiopharm GmbH	Mono-malatsalz von tofacitinib
ES2657912T3 (es) *	2012-07-17	2018-03-07	Glaxosmithkline Intellectual Property (No. 2) Limited	Indolcarbonitrilos como moduladores selectivos de los receptores de andrógenos
WO2014016338A1 (en)	2012-07-25	2014-01-30	Lek Pharmaceuticals D.D.	New synthetic route for the preparation of 3-amino-piperidine compounds
CN102875555A (zh) *	2012-09-27	2013-01-16	同济大学	一种JAK抑制剂Tofacitinib的合成方法
CN104955803B (zh) *	2012-11-30	2017-11-28	斯洛文尼亚莱柯制药股份有限公司	通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
US9481679B2 (en)	2012-12-17	2016-11-01	Sun Pharmaceutical Industries Limited	Process for the preparation of tofacitinib and intermediates thereof
US9670160B2 (en)	2012-12-28	2017-06-06	Glenmark Pharmaceuticals Limited	Process for the preparation of tofacitinib and intermediates thereof
CN103073552B (zh) *	2013-02-05	2015-08-12	华润赛科药业有限责任公司	一种无定型枸橼酸托法替尼的制备方法
EP2958921B1 (de) *	2013-02-22	2017-09-20	Pfizer Inc	Pyrrolo[2, 3 -d]pyrimidinderivate als inhibitoren von janus kinasen (jak)
WO2014174073A1 (en)	2013-04-26	2014-10-30	Sandoz Ag	Sustained release formulations of tofacitinib
CN104447752A (zh) *	2013-09-16	2015-03-25	天津市汉康医药生物技术有限公司	一种托法替尼水合物及其制备方法
CN104447751A (zh) *	2013-09-16	2015-03-25	天津市汉康医药生物技术有限公司	一种托法替尼化合物
CN104292231B (zh) *	2013-09-17	2016-11-30	广东东阳光药业有限公司	一种枸橼酸托法替尼的制备方法
CN105873931B (zh) *	2013-10-08	2018-10-16	广东东阳光药业有限公司	托法替布柠檬酸盐
CN103819474A (zh) *	2013-11-04	2014-05-28	湖南华腾制药有限公司	一种托法替尼的制备方法
PT3318565T (pt)	2013-12-05	2021-05-28	Pfizer	Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
ES2865058T3 (es)	2013-12-09	2021-10-14	Unichem Lab Ltd	Un proceso mejorado para la preparación de (3R,4R)-(1-bencil-4-metilpiperidin-3-il)-metilamina
CN104774206A (zh) *	2014-01-14	2015-07-15	江苏柯菲平医药股份有限公司	制备枸橼酸托伐替尼晶型a的新方法
CN103755624B (zh) *	2014-01-20	2018-10-09	上海博氏医药科技有限公司	一种哌啶衍生物的合成方法
CN105085527A (zh) *	2014-05-20	2015-11-25	南京海纳医药科技有限公司	高效合成托法替尼的方法
ES2750655T3 (es)	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
KR101710127B1 (ko) *	2014-08-29	2017-02-27	한화제약주식회사	야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
US9567341B2 (en) *	2014-09-15	2017-02-14	Rugen Holdings (Cayman) Limited	Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
CN104530053A (zh) *	2014-12-08	2015-04-22	合肥远志医药科技开发有限公司	一种药用晶型枸橼酸托法替尼的制备方法
CN104530055A (zh) *	2014-12-23	2015-04-22	南京艾德凯腾生物医药有限责任公司	枸橼酸托法替布的制备方法
CN105837574B (zh) *	2015-02-02	2018-03-02	四川大学	N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
CN104710346B (zh) *	2015-02-15	2017-04-12	江苏苏利精细化工股份有限公司	一种合成顺式‑1‑苄基‑3‑甲氨基‑4‑甲基‑哌啶的方法
US20180010158A1 (en) *	2015-02-20	2018-01-11	Sun Pharmaceutical Industries Limited	A process for the preparation of tofacitinib citrate
CN104761556B (zh) *	2015-03-21	2017-06-23	河北国龙制药有限公司	托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
CN104860872A (zh) *	2015-03-27	2015-08-26	天津药物研究院有限公司	一种双-(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺l-二对甲基苯甲酰酒石酸盐的合成方法
EP3078665A1 (de)	2015-04-10	2016-10-12	OLON S.p.A.	Effizientes verfahren zur herstellung von tofacitinib-citrat
CN104788461A (zh) *	2015-04-30	2015-07-22	南京臣功制药股份有限公司	一种适合枸橼酸托法替尼工业化的生产方法
ES2928757T3 (es)	2015-05-01	2022-11-22	Pfizer	Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
CN104987339A (zh) *	2015-07-29	2015-10-21	张燕梅	一种枸橼酸托法替布的合成方法
EP3416965B1 (de)	2016-02-16	2020-10-07	Zoetis Services LLC	Verfahren zur herstellung von 7h-pyrrolo[2,3-d]pyrimidin-verbindungen
CN105732641A (zh) *	2016-03-28	2016-07-06	南通常佑药业科技有限公司	一种JAKs抑制剂药物托法替尼的制备方法
CN105884781B (zh) *	2016-04-18	2018-04-20	山东罗欣药业集团股份有限公司	一种枸橼酸托法替布的制备方法
CN106146517B (zh) *	2016-06-20	2018-08-28	山东大学	一种枸橼酸托法替尼的合成方法
CN106188064A (zh) *	2016-07-07	2016-12-07	国药集团容生制药有限公司	一种N‑甲基‑N‑((3R，4R)‑4‑甲基吡啶‑3‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑4‑胺的制备方法
CN105949204A (zh) *	2016-07-25	2016-09-21	国药集团容生制药有限公司	一种N-((3R，4R)-1-苄基-4-甲基吡啶-3-基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺的制备方法
EP3421455B1 (de) *	2017-06-29	2019-03-27	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Verbessertes verfahren zur herstellung von chiralen 3-amino-piperidinen, nützliche zwischenprodukte zur herstellung von tofacitinib
CN109293682A (zh) *	2017-07-25	2019-02-01	重庆医药工业研究院有限责任公司	一种托法替布杂质及其制备方法
CN107698595A (zh) *	2017-09-23	2018-02-16	江苏正大清江制药有限公司	一种枸橼酸托法替布有关物质的制备方法
CN107793418B (zh) *	2017-10-24	2020-08-04	扬子江药业集团有限公司	一种枸橼酸托法替布的工业化生产方法
CN108640923A (zh) *	2018-07-09	2018-10-12	湖南天地恒制药有限公司	一种托法替布关键中间体的制备方法
CN108822112B (zh) *	2018-08-13	2019-12-20	山东罗欣药业集团恒欣药业有限公司	一种托法替尼化合物的制备方法
CN109608468B (zh) *	2018-12-29	2020-09-29	成都倍特药业股份有限公司	一种枸橼酸托法替布杂质及其合成方法和用途
KR102131107B1 (ko) *	2019-01-15	2020-07-07	주식회사 다산제약	3-아미노-피페리딘 화합물의 신규한 제조 방법
CN109503462B (zh) *	2019-01-21	2022-03-25	内蒙古京东药业有限公司	托法替布中间体(3r，4r)-n，4-二甲基-1-苄基-3-哌啶胺的合成方法
CN109761884B (zh) *	2019-01-30	2020-03-31	湖北扬信医药科技有限公司	一种手性胺b的制备方法及其应用
WO2020183295A1 (en)	2019-03-13	2020-09-17	Intas Pharmaceuticals Ltd.	Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
CN113993585A (zh)	2019-03-27	2022-01-28	英矽智能科技知识产权有限公司	双环jak抑制剂及其用途
CN113614069B (zh) *	2019-04-05	2024-05-28	柳韩洋行	用于制备(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺或其盐的方法以及使用其制备托法替尼的方法
CN110724146B (zh) *	2019-11-04	2022-03-11	四川大学	一种枸橼酸托法替布的制备方法
WO2022040172A1 (en)	2020-08-18	2022-02-24	Incyte Corporation	Process and intermediates for preparing a jak1 inhibitor
KR20230096973A (ko)	2020-08-18	2023-06-30	인사이트 코포레이션	Jak 저해제를 제조하기 위한 방법 및 중간체
CN112679508B (zh) *	2021-03-09	2021-08-10	正大天晴药业集团南京顺欣制药有限公司	一种托法替布中间体的制备方法
CN113248509B (zh) *	2021-05-17	2022-10-04	上海中西三维药业有限公司	一种枸橼酸托法替布中间体的制备方法
CN113735860A (zh) *	2021-08-26	2021-12-03	安徽鼎旺医药有限公司	一种枸橼酸托法替布的合成方法
CN114685515A (zh) *	2022-03-15	2022-07-01	上海蓝乐鸟实业有限公司	一种托法替尼的制备方法
CN114835714A (zh) *	2022-04-01	2022-08-02	上海蓝乐鸟实业有限公司	一种托法替尼的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0710877A (ja) *	1993-06-24	1995-01-13	Teijin Ltd	４―ヘテロアリサイクリック―ピロロ［２，３―ｄ］ピリミジン
DE60007552T2 (de)	1999-12-10	2004-09-23	Pfizer Products Inc., Groton	PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
KR100875380B1 (ko)	2001-06-23	2008-12-23	아벤티스 파마슈티칼스 인크.	단백질 키나제 억제제로서의 피롤로피리미딘
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
US20040012627A1 (en)	2002-07-17	2004-01-22	Sany Zakharia	Configurable browser for adapting content to diverse display types
JP2006503826A (ja)	2002-09-06	2006-02-02	スミスクライン・ビーチャム・コーポレイション	ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
MXPA05005403A (es)	2002-11-21	2005-08-03	Pfizer Prod Inc	Derivados de 3-amino-piperadina y metodos de fabricacion.
AU2004233897A1 (en) *	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates

2006
- 2006-07-17 PT PT06779900T patent/PT1913000E/pt unknown
- 2006-07-17 AT AT06779900T patent/ATE540952T1/de active
- 2006-07-17 KR KR1020087002240A patent/KR100987870B1/ko not_active IP Right Cessation
- 2006-07-17 BR BRPI0613876-4A patent/BRPI0613876A2/pt not_active IP Right Cessation
- 2006-07-17 CN CNA2006800279013A patent/CN101233138A/zh active Pending
- 2006-07-17 ES ES06779900T patent/ES2377771T3/es active Active
- 2006-07-17 AU AU2006273762A patent/AU2006273762A1/en not_active Abandoned
- 2006-07-17 DK DK06779900.7T patent/DK1913000T3/da active
- 2006-07-17 EP EP06779900A patent/EP1913000B1/de active Active
- 2006-07-17 US US11/996,899 patent/US8232394B2/en active Active
- 2006-07-17 SI SI200631245T patent/SI1913000T1/sl unknown
- 2006-07-17 WO PCT/IB2006/002048 patent/WO2007012953A2/en active Application Filing
- 2006-07-17 RU RU2008103279/04A patent/RU2384583C2/ru not_active IP Right Cessation
- 2006-07-17 PL PL06779900T patent/PL1913000T3/pl unknown
- 2006-07-17 SG SG201102177-1A patent/SG170783A1/en unknown
- 2006-07-17 NZ NZ565363A patent/NZ565363A/en not_active IP Right Cessation
- 2006-07-17 CA CA2614907A patent/CA2614907C/en active Active
- 2006-07-17 MX MX2008001334A patent/MX2008001334A/es active IP Right Grant
- 2006-07-27 AR ARP060103254A patent/AR056004A1/es unknown
- 2006-07-28 TW TW095127592A patent/TWI319402B/zh not_active IP Right Cessation
- 2006-07-28 JP JP2006206218A patent/JP4052523B2/ja active Active
2007
- 2007-12-24 IL IL188372A patent/IL188372A0/en unknown
2008
- 2008-01-09 ZA ZA200800284A patent/ZA200800284B/xx unknown
2012
- 2012-02-06 CY CY20121100122T patent/CY1112319T1/el unknown
- 2012-06-20 US US13/528,099 patent/US8309716B2/en active Active

Also Published As

Publication number	Publication date
AR056004A1 (es)	2007-09-12
US20110288297A1 (en)	2011-11-24
PT1913000E (pt)	2012-02-28
NZ565363A (en)	2010-03-26
CN101233138A (zh)	2008-07-30
KR20080031338A (ko)	2008-04-08
KR100987870B1 (ko)	2010-10-13
WO2007012953A2 (en)	2007-02-01
TW200745119A (en)	2007-12-16
BRPI0613876A2 (pt)	2011-02-15
SI1913000T1 (sl)	2012-02-29
JP4052523B2 (ja)	2008-02-27
WO2007012953A3 (en)	2007-05-18
MX2008001334A (es)	2008-03-24
PL1913000T3 (pl)	2012-05-31
TWI319402B (en)	2010-01-11
EP1913000A2 (de)	2008-04-23
EP1913000B1 (de)	2012-01-11
ES2377771T3 (es)	2012-03-30
US8232394B2 (en)	2012-07-31
CA2614907A1 (en)	2007-02-01
US8309716B2 (en)	2012-11-13
IL188372A0 (en)	2008-04-13
ZA200800284B (en)	2008-12-31
AU2006273762A1 (en)	2007-02-01
SG170783A1 (en)	2011-05-30
RU2008103279A (ru)	2009-08-10
RU2384583C2 (ru)	2010-03-20
CY1112319T1 (el)	2015-12-09
DK1913000T3 (da)	2012-03-12
US20120259115A1 (en)	2012-10-11
CA2614907C (en)	2012-02-28
JP2007039455A (ja)	2007-02-15

Publication	Publication Date	Title
ATE540952T1 (de)	2012-01-15	Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese
ATE486076T1 (de)	2010-11-15	6-carboxy-normorphinan-derivate, ihre synthese und verwendung
DK3090748T3 (da)	2019-05-27	Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
SI1913001T1 (sl)	2013-11-29	(r)-n-metilnaltrekson, postopki za njega sintezo in njega farmacevtsko uporabo
ATE543808T1 (de)	2012-02-15	5,6-ring-annelierte indolderivate und ihre verwendung
ATE550315T1 (de)	2012-04-15	Pestizid-bi-phenyl-amidin-derivate
DE602005000542D1 (de)	2007-03-22	Vorform, Innenhochdruckumformverfahren und so hergestelltes Produkt
DE602006020277D1 (de)	2011-04-07	Warenverpackung
ATE502927T1 (de)	2011-04-15	Pestizide pyrimidinyloxysubstituierte phenylamidinderivate
DK1957073T3 (da)	2014-05-12	Lægemiddel
ATE487718T1 (de)	2010-11-15	Substituierte bizyklische pyrimidonderivate
DE602006010343D1 (de)	2009-12-24	Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de)	2010-11-15	Azaindol-2-carboxamid-derivate
ATE527255T1 (de)	2011-10-15	Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da)	2012-10-22	Tiglien-3-onderivater
IL188896A0 (en)	2008-04-13	Diazepinoquinolines, synthesis thereof, and intermediates thereto
FIU20070081U0 (fi)	2007-03-01	Saniteettituote
HK1136159A1 (en)	2010-06-25	Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use
FR2888844B1 (fr)	2014-08-08	Procede de synthese.
DE602006014973D1 (de)	2010-07-29	Neuartige cercosporamidderivate
DK1876916T3 (da)	2013-02-04	Produkt
DE602006019103D1 (de)	2011-02-03	Fluorsubstituierte 2-oxo-azepan-derivate
ATE541837T1 (de)	2012-02-15	Oxaphenanthren-derivate
ATE374761T1 (de)	2007-10-15	Syntheseverfahren und benzoxathiepinzwischenprodukte